Zymogenetics, Inc.

Alpine Immune Sciences, Inc.

University of Washington

Novo Nordisk A/s

Bristol-myers Squibb Compnay

Joseph Leon Kuijper

Cindy A Sprecher

Francis J Grant

Angela K Hammond

Maria M Dasovich

Jane A Gross

Mark F Maurer

Theodore E Whitmore

Ryan Swanson

Stacey R Dillon

Michael G Kornacker

Scott R Presnell

Julia E Novak

Zeren Gao

Lawrence Evans

Daniel William Demonte

Donald C Foster

Si Lok

Rolf E Kuestner

Paul O Sheppard

Wayne R Kindsvogel

Mark W Rixon

Vibeke Westphal Stennicke

Patrick J O'Hara

Christine Brender Read

Siv Annegrethe Hjorth

Laura J Jelinek

Stanford L Peng

Mark Heipel

Xiaoting Tang

John W Forstrom

David S Weigle

Dan Ardourel

Richard D Holly

Frederick S Hagen

Joyce M Lehner

Catherine E Lofton-Day

Kenneth Kaushansky

Pieter J Oort

Patrick J O'hara

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

CTLA-4 variant immunomodulatory proteins and uses thereof

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunomodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

April and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Provided herein are immunomodulatory proteins comprising variant CD112 and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

CD112 variant immunomodulatory proteins and uses thereof

Provided herein are immunomodulatory proteins comprising variant PD-L2 and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

PD-L2 variant immunomodulatory proteins and uses thereof

Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

CD80 variant immunomodulatory proteins and uses thereof

Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.

Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

Methods of producing a zcytor17 heterodimeric cytokine receptor

Growing community of inventors

Kenmore, WA, United States of America

Joseph Leon Kuijper